Study S000054

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study to Evaluate the Safety, Efficacy and Tolerability of Ofirnoflast (HT-6184) and Semaglutide in Obese or Overweight Participants With Type 2 Diabetes Mellitus (T2DM)

ClinicalTrials.gov record

Registration

Registration: NCT07172867
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: WITHDRAWN
Enrollment: 0
Start: 2026-01-06
Primary completion: 2026-01-23
Lead sponsor: Halia Therapeutics, Inc.
Conditions: Diabetes Mellitus, Type 2; Obesity
Interventions: DRUG:HT-6184; DRUG:HT-6184 Matching Placebo; DRUG:Semaglutide 1 mg
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Assess glycemic control using HbA1c (%) [From first dose through End of Study (up to 12 weeks per participant)]
Assess weight loss using body weight measurements [From first dose through End of Study (up to 12 weeks per participant)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.